Praluent (Alirocumab) Anesthesia and Perioperative Interactions: What Patients and Clinicians Need to Know

Does Alirocumab Interact Directly With Anesthetic Drugs?

Alirocumab does not interact pharmacokinetically with any currently approved general, regional, or neuraxial anesthetic agent. Because alirocumab is a large monoclonal antibody eliminated by intracellular proteolytic catabolism rather than hepatic CYP450 enzymes, it does not compete for the metabolic pathways used by propofol, fentanyl, sevoflurane, ketamine, or neuromuscular blockers [1]. The FDA-approved prescribing information for alirocumab lists no drug-drug interactions with anesthetics [2].

Why Monoclonal Antibodies Behave Differently Than Small-Molecule Drugs

Small-molecule lipid drugs such as atorvastatin rely heavily on CYP3A4 and OATP1B1 transporters. Co-administration of CYP3A4 inhibitors in the operating room (such as diltiazem used for rate control) can raise statin plasma levels and increase myopathy risk. Alirocumab carries none of that exposure. Protein-binding displacement, which is a common mechanism of anesthetic drug interactions, does not apply to a 146-kDa antibody whose target, PCSK9, is a circulating plasma protein [1].

What "No CYP Interaction" Means in Practice

The absence of CYP450 involvement means that:

• Induction agents (propofol, etomidate, thiopental) do not alter alirocumab clearance.
• Volatile anesthetics (sevoflurane, desflurane, isoflurane) do not compete for metabolic enzymes.
• Opioid analgesics (fentanyl, remifentanil, morphine) have no shared pathway.
• Neuromuscular blocking agents (rocuronium, vecuronium, succinylcholine) are unaffected.

Clinicians should note that this absence of pharmacokinetic risk does not remove the need to disclose alirocumab use during preoperative assessment, because the underlying cardiovascular disease driving its prescription is itself a perioperative risk factor.

Should Alirocumab Be Continued or Held Before Surgery?

There is no evidence-based recommendation to discontinue alirocumab before elective surgery. The 2018 AHA/ACC Multisociety Cholesterol Guideline states that high-intensity statin therapy should be continued perioperatively in patients with established atherosclerotic cardiovascular disease (ASCVD), and the same principle extends to adjunctive PCSK9 inhibitor therapy [3]. Given alirocumab's long half-life of approximately 17 to 20 days, even a missed single injection before surgery does not meaningfully change LDL-C during the perioperative window [2].

Timing the Injection Around Surgery

Alirocumab is administered subcutaneously every 2 weeks (75 mg or 150 mg) or every 4 weeks (300 mg). If a scheduled injection date falls within 24 to 48 hours of a planned procedure, the practical approach is:

1. Administer the injection at least 24 hours before surgery so the injection site is stable.
2. If the injection falls on the day of surgery, defer it until the patient is recovered and tolerating subcutaneous medications.
3. Resume on the normal schedule at the next window; no loading dose is required after a single missed injection [2].

The American College of Surgeons' perioperative medicine guidance does not list PCSK9 inhibitors among drugs requiring mandatory preoperative discontinuation, unlike anticoagulants or immunosuppressants [4].

Subcutaneous Injection Sites and Surgical Fields

One practical concern is the injection site. Alirocumab is injected into the abdomen, thigh, or upper arm. If a surgical field overlaps an active injection site, the patient should rotate to a different anatomical region at least one injection cycle before the operation to avoid operating on a recently injected area with localized inflammation.

Alirocumab and Cardiovascular Risk Reduction Around High-Risk Surgery

For patients undergoing major noncardiac surgery, the perioperative period carries heightened cardiovascular risk. Plaque rupture, endothelial stress, and sympathetic activation during surgery can precipitate acute coronary syndrome in patients with underlying ASCVD [5]. Maintaining LDL-C control through this window is not merely a housekeeping measure.

Evidence from ODYSSEY OUTCOMES

The ODYSSEY OUTCOMES trial (N=18,924) enrolled patients within 1 to 12 months after acute coronary syndrome (ACS) and randomized them to alirocumab 75 to 150 mg every 2 weeks versus placebo on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced major adverse cardiovascular events (MACE) by 15% relative to placebo (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001) [6]. Many participants in this trial underwent surgical procedures during follow-up, and no safety signals related to anesthesia or perioperative bleeding were observed in the reported adverse event data [6].

LDL-C Targets and Perioperative Cardiovascular Protection

The 2018 AHA/ACC Cholesterol Guideline recommends an LDL-C goal of <70 mg/dL in patients with ASCVD, and <55 mg/dL in very high-risk ASCVD [3]. A patient on alirocumab approaching surgery with an LDL-C below 70 mg/dL has substantially lower plaque vulnerability compared to an undertreated patient. The ESC/EAS 2019 Dyslipidaemia Guidelines quote: "For patients in the very high-risk category, an LDL-C reduction of at least 50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) is recommended" [7].

Holding alirocumab before cardiac surgery or any major procedure in a patient with established ASCVD would predictably allow LDL-C to rebound over subsequent weeks, potentially increasing vulnerability during the recovery phase when inflammatory stress remains elevated.

Alirocumab and Co-Prescribed Drugs Common in the Perioperative Setting

Statins

The most relevant co-therapy interaction is not between alirocumab and anesthetic agents directly. It is between statins and the perioperative environment. Statin-associated myopathy risk increases when patients are immobilized, volume-depleted, or receiving nephrotoxic agents. Alirocumab itself does not cause myopathy and does not amplify statin-related creatine kinase (CK) elevations [1]. In the ODYSSEY LONG TERM trial (N=2,341), CK elevations greater than 3 times the upper limit of normal occurred in 2.5% of alirocumab patients versus 2.0% placebo, a difference that was not statistically significant [8].

Anticoagulants and Antiplatelet Agents

Patients on alirocumab for ASCVD often co-prescribe antiplatelet therapy (aspirin, clopidogrel) or anticoagulants (rivaroxaban, apixaban). Alirocumab has no anticoagulant mechanism. Bleeding risk around surgery is determined by the antiplatelet and anticoagulant regimen, not by alirocumab [2]. Surgeons and anesthesiologists should manage anticoagulant holds per standard bridging protocols independently of alirocumab status.

NSAIDs and Postoperative Analgesia

Postoperative NSAID use, common for multimodal analgesia, carries cardiovascular risk in patients with established ASCVD. This risk is entirely independent of alirocumab's mechanism. The cardiovascular benefit alirocumab provides through LDL-C reduction does not offset acute NSAID-driven prostaglandin inhibition in the perioperative period. Clinicians should follow ACC/AHA guidance on limiting NSAID duration in patients with existing coronary artery disease [5].

Corticosteroids

Perioperative corticosteroids (dexamethasone for postoperative nausea, stress-dose hydrocortisone for adrenal insufficiency) increase LDL-C transiently through several mechanisms including PCSK9 upregulation [9]. This does not interact with alirocumab pharmacokinetically, but it does mean that a patient on alirocumab receiving high-dose corticosteroids may see a blunted LDL-lowering response for a brief period. Clinicians should not interpret a transient LDL-C rise during steroid courses as treatment failure.

Alirocumab and Alcohol: What the Evidence Shows

"Can I drink on Praluent?" is a common patient question, and the answer requires separating pharmacokinetic concern from metabolic concern. Alcohol does not inhibit or induce the proteolytic pathways that clear alirocumab, and no pharmacokinetic interaction has been described [2]. Acute alcohol ingestion does, however, raise plasma triglyceride levels, which may worsen mixed dyslipidemia independent of alirocumab's LDL-specific mechanism.

Chronic heavy alcohol use causes hepatic dysfunction, which can reduce the liver's capacity to absorb LDL particles, thereby blunting the downstream effect of PCSK9 inhibition. Patients consuming more than 14 standard drinks per week should be counseled that alcohol may reduce the net lipid benefit of alirocumab therapy, even if the drug itself is unaffected pharmacokinetically.

Moderate alcohol consumption (1 to 2 drinks per day) has not been shown to reduce the efficacy of PCSK9 inhibitor therapy in clinical trials, though no ODYSSEY sub-trial specifically studied this variable.

Preoperative Assessment Checklist for Patients on Alirocumab

The following framework is designed for anesthesiologists and surgical teams conducting preoperative medication review in patients on alirocumab. It consolidates the perioperative considerations above into a single workflow.

Step 1. Confirm indication. Is the patient on alirocumab for primary hypercholesterolemia, heterozygous familial hypercholesterolemia (HeFH), or post-ACS secondary prevention? The cardiovascular risk profile differs meaningfully by indication and should inform intraoperative monitoring intensity.

Step 2. Review LDL-C trend. Obtain a lipid panel within 4 to 8 weeks before major elective surgery. A patient with LDL-C below 70 mg/dL has achieved target; one above 100 mg/dL on maximum-dose alirocumab warrants cardiology consultation before high-risk surgery.

Step 3. Check injection schedule. Map the last injection date against the surgery date. If the next scheduled injection falls within 24 hours of the operation, administer it the day before or defer until post-recovery per the guidance above.

Step 4. Audit the co-medication list. Identify all CYP3A4-sensitive drugs in the anesthetic plan (statins, diltiazem, amiodarone). Alirocumab does not add to that risk, but statin dose may need temporary adjustment if rhabdomyolysis risk is elevated by prolonged immobilization or tourniquet use.

Step 5. Document and communicate. Note alirocumab on the anesthesia intake form. Ensure the PACU team knows the patient is on PCSK9 inhibitor therapy not because it changes their management, but because it reflects high underlying cardiovascular risk requiring standard ASCVD monitoring.

Special Populations: Cardiac Surgery and High-Risk Procedures

Coronary Artery Bypass Grafting (CABG)

Patients undergoing CABG are among the highest-risk candidates for perioperative cardiovascular events. Preoperative LDL-C lowering reduces vein graft failure rates, and PCSK9 inhibitors have demonstrated the ability to reduce LDL-C by 44 to 61% on top of statin therapy [8]. A 2022 analysis in the Journal of the American College of Cardiology found that patients with LDL-C below 55 mg/dL at time of ACS had lower rates of recurrent events, supporting aggressive continuation of lipid-lowering regimens including PCSK9 inhibitors into the operative period [10].

No alirocumab-specific CABG trial exists, but the pharmacological logic of maintaining LDL-C control through surgery is well-supported by the ODYSSEY OUTCOMES data described above.

Carotid Endarterectomy and Peripheral Vascular Surgery

Patients with peripheral arterial disease or carotid stenosis often carry LDL-C levels well above guideline targets despite statin therapy. Alirocumab is approved for this population as an adjunctive agent. The perioperative concern in vascular surgery is plaque stability: higher LDL-C correlates with softer, more rupture-prone atherosclerotic plaques. Maintaining alirocumab through a carotid endarterectomy or lower-extremity bypass has theoretical benefit and no established risk.

Patients With Familial Hypercholesterolemia

Patients with heterozygous familial hypercholesterolemia (HeFH) have baseline LDL-C levels of 190 to 400 mg/dL and are at markedly elevated perioperative cardiovascular risk even when treated. The FDA approved alirocumab specifically for HeFH in 2015 [2]. In these patients, any interruption of alirocumab therapy carries greater consequence because their baseline LDL-C without therapy is substantially higher than the general dyslipidemia population.

What Patients Should Tell Their Surgical and Anesthesia Teams

Patients often do not volunteer information about injectable biologics during preoperative medication review, assuming they are "just cholesterol shots." Three things every patient on alirocumab should communicate before surgery:

• "I inject Praluent every 2 weeks (or once a month). My last injection was on [date]."
• "I take it for [indication: high cholesterol / heart attack prevention / familial hypercholesterolemia]."
• "My most recent LDL-C was [value] mg/dL."

These three data points allow the anesthesiologist to calibrate cardiovascular monitoring, ensure the injection schedule does not conflict with the surgical date, and avoid any misinterpretation of alirocumab as an anticoagulant or immunosuppressant requiring mandatory hold.

The European Society of Anaesthesiology's 2022 preoperative evaluation guidelines note that a comprehensive medication history must include all biologic agents, even those perceived by patients as low-risk [11].